Статья
Артериальное давление, показатели липидного спектра и полиморфизмы генов аполипопротеина А1 и параоксоназы 1-го типа у больных абдоминальным ожирением
Цель исследования — изучение G-75A и C+83T полиморфизмов гена аполипопротеина А1 (APOA1) и Q192R полиморфизма гена параоксоназы 1-го типа (PON1) и их взаимосвязь с уровнем артериального давления и показателями липидного обмена у больных абдоминальным ожирением. Материалы и методы. Обследованы 222 больных абдоминальным ожирением (57 мужчин и 165 женщин), жители Санкт-Петербурга. Результаты. Выявлена высокая встречаемость артериальной гипертензии (61 %) и различных видов дислипидемий. Проанализирована частота аллелей генов аполипопротеина А1 и параоксоназы 1-го типа у больных абдоминальным ожирением. Представлены данные относительно ген-генных взаимодействий и уровня артериального давления, выраженности ожирения и изменений липидного профиля в обследованной группе больных.
1. Aekplakom W., Mo-Suwan L. Prevalence of obesity in Thailand // Obes. Rev. — 2009. — Vol. 10, № 6. — 589-592.
2. Despres J.P. Cardiovascular disease under the influence of excess visceral fat // Crit. Pathw. Cardiol. — 2007. — Vol. 6, № 2. — Р. 51-59.
3. Kathiresan S. Lp(a) lipoprotein redux-from curious molecule to causal risk factor // N. Engl. J. Med. — 2009. — Vol. 361, № 26. — Р. 2573-2574.
4. Lee Y.H., Choi S.H., Lee K.W., Kim D.J. Apolipoprotein B/ A1 ratio is associated with free androgen index and visceral adiposity and may be an indicator of metabolic syndrome in male children and adolescents // Clin. Endocrinol. (Oxf). — 2011. — Vol. 74, № 5. — Р. 579-586.
5. Gupta N., Gill K., Singh S. Paraoxonases: structure, gene polymorphism and role in coronary artery disease // Indian J. Med. Res. — 2009. — Vol. 130, № 4. — Р. 361-368.
6. Mendoza M.I., Dos Res R.P., Freitas A.I. et al. Interaction of paraoxonase-192 polymorphism with low HDL-cholesterol in coronary artery disease risk // Rev. Port. Cardiol. — 2010. — Vol. 29, № 4. — P. 571-580.
7. Primo-Parmo S.L., Sorenson R.C., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family // Genomics. — 1996. — Vol. 33, № 3. — Р. 498-507.
8. Hegele R.A. Paraoxonase genes and disease // Ann. Int. Med. — 1999. — Vol. 31, № 3. — Р. 217-224.
9. Aviram M., Hardak E., Vaya J. et al. Human serum paraoxo-nase (PON) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities // Circulation. — 2000. — Vol. 101, № 21. — Р. 2510-2517.
10. Aviram M., Rosenblat M., Bisgaier C.L. et al... Paraoxo-nase inhibits high-density lipoprotein oxidation and preserves its functions // J. Clin. Invest. — 1998. — Vol. 101, № 8. — Р. 1581-1590.
11. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis // Arterioscler. Thromb. Vasc. Biol. — 2001. — Vol. 21, № 4. — Р. 473-480.
12. Rodrigo L., Mackness B., Durrington P.N, Hernandez A., Mackness M.I. Hydrolysis of platelet-activating factor by human serum paraoxonase // Biochem. J. — 2001. — Vol. 354, Pt. 1. — P. 1-7.
13. Billecke S., Draganov D., Counsell R. et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters // Drug Metab. Dispos. — 2000. — Vol. 28, № 11. — P. 1335-1342.
14. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation // J. Biol. Chem. — 2000. — Vol. 275, № 6. — P. 3957-3962.
15. Getz G.S., Reardon C.A. Paraoxonase, a cardioprotective enzyme: continuing issues // Curr. Opin. Lipidol. — 2004. — Vol. 15, № 3. — P. 261-266.
16. Aviram M., Rosenblat M. Paraoxonases and cardiovascular diseases: Pharmacological and nutritional influences // Curr. Opin. Lipidol. — 2005. — Vol. 16, № 4. — P. 393-399.
17. James R.W., Deakin S.P. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability and activity // Free Radic. Biol. Med. — 2004. — Vol. 37, № 12. — P. 1986-1994.
18. Kaplan N., Aviram M. Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase // Clin. Chem. Lab. Med. — 1999. — Vol. 37, № 8. — P. 777-787.
19. Ticozzi N., LeClerc A.L., Keagle PJ. et al. Paraoxonase gene mutations in amyotrophic lateral sclerosis // Ann. Neurol. — 2010. — Vol. 68, № 1. — Р. 102-107.
20. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism // Nat. Genet. — 1993. — Vol. 3, № 1. — P. 73-76.
21. Talmud P.J., Ye S., Humphries S.E. Polymorphism in the promoter region of the apolipoprotein AI gene associated with differences in apolipoprotein AI levels: the European Atherosclerosis Research Study // Genet. Epidemiol. — 1994. — Vol. 11, № 3. — P. 265-280.
22. Reguero J.R., Cubero G.I., Batalla A. et al. Apolipoprotein A1 gene polymorphisms and risk of early coronary disease // Cardiology. — 1998. — Vol. 90, № 3. — Р. 231-235.
23. Pulkkinen A., Viitanen L., Kareinen A. et al. MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein A1 gene is associated with elevated levels of HDL cholesterol and apolipoprotein A1 in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease // Diabetes Care. — 2000. — Vol. 23, № 6. — Р. 91-795.
24. Dawar R., Gurtoo A., Singh R. Apolipoprotein A1 gene polymorphism (G-75A and C+83T) in patients with myocardial infarction: a pilot study in a north Indian population // Am. J. Clin. Pathol. — 2010. — Vol. 134, № 2. — Р. 249-255.
25. Sorkin S.C., Forestiero F.J., Hirata M.H. et al. APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals // Clin. Chem. Lab. Med. — 2005. — Vol. 43, № 12. — Р. 1339-1345.
26. Rice N., Bandinelli S., Corsi A. et al. The paraoxonase (PON1) Q192R polymorphism is not associated with poor health status or depression in the ELSA or InCHIANTI studies // Int. J. Epidemiol. — 2009. — Vol. 38, № 5. — P. 1374-1379.
27. Birjmohun R.S., Vergeer M., Stroes E.S.G. et al. Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study // PLoS One. — 2009. — Vol. 4, № 8. — P. e6809.
28. Koncsos P., Seres I., Harangi M. et al. Human paraoxo-nase-1 activity in childhood obesity and its relation to leptin and adiponectin levels // Pediatr. Res. — 2010. — Vol. 67, № 3. — P. 309-313.
29. Kougias P., Chai H., Lin P.H. et al. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease // J. Surg. Res. — 2005. — Vol. 126, № 1. — Р. 121-129.
30. Bajnok L., Seres I., Varga Z. et al. Relationship of endogenous hyperleptinemia to serum paraoxonase 1, cholesteryl ester transfer protein, and lecithin cholesterol acyltransferase in obese individuals // Metabolism. — 2007. — Vol. 56, № 11. — Р. 1542-1549.
31. Nishio E., Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme’s free thiols // Biochem. Biophys. Res. Commun. — 1997. — Vol. 236, № 2. — P. 289-293.
32. Dirican M., Akca R., Sarandol E., Dilek K. Serum paraoxo-nase activity in uremic predialysis and hemodialysis patients // J. Nephrol. — 2004. — Vol. 17, № 6. — Р 813-818.
33. Deakin S., Leviev I., Gomaraschi M., Calabresi L., Fran-ceschini G., James R.W. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism // J. Biol. Chem. — 2002. — Vol. 277, № 6. — Р 4301-4308.
34. van Himbergen T.M., Roest M., de Graaf J. et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia // J. Lipid Res. — 2005. — Vol. 46, № 3. — Р 445-451.
35. Agrawal S., Tripathi G., Prajnya R. et al. Paraoxonase 1 gene polymorphisms contribute to coronary artery disease risk among north Indians // Indian J. Med. Sci. — 2009. — Vol. 63, № 8. — P. 335-344.
36. Banerjee I. Relationship between Paraoxonase 1 (PON1) gene polymorphisms and susceptibility of stroke: a meta-analysis // Eur. J. Epidemiol. — 2010. — Vol. 25, № 7. — P. 449-458.
37. Garin M.C., James R.W., Dussoix P. et al. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentrations of enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes // J. Clin. Invest. — 1997. — Vol. 99, № 1. — P. 62-66.